Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMC6PKJ)

Drug Name	CYC140 DMC6PKJ
Synonyms	Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-
Drug Type	Small molecular drug
Structure
Structure	3D MOL is unavailable			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Myelodysplastic syndrome	DISYHNUI	2A37	Phase 1	[1]
Acute myeloid leukaemia	DIS0BM1I	2A60	Phase 1	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03884829) A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS. U.S. National Institutes of Health.